Cardiol Therapeutics Inc Class A Total Assets
Cardiol Therapeutics Inc Class A total assets. Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) holds total assets worth CA$23.62 Million CAD (≈ $17.09 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Cardiol Therapeutics Inc Class A for the company's overall valuation and market capitalisation.
Total Assets of Cardiol Therapeutics Inc Class A (2017–2025)
Total assets of Cardiol Therapeutics Inc Class A from 2017 to 2025. This chart illustrates how Cardiol Therapeutics Inc Class A's total assets have evolved over time, based on quarterly financial data. See Cardiol Therapeutics Inc Class A (CRDL) stock price for real-time trading data and today's change.
Cardiol Therapeutics Inc Class A - Asset Composition Analysis
Cardiol Therapeutics Inc Class A Total Assets Breakdown (December 2025)
Cardiol Therapeutics Inc Class A total assets breakdown as of December 2025. Cardiol Therapeutics Inc Class A's total assets of CA$23.62 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$21.42 Million | 90.7% |
| Accounts Receivable | CA$226.19K | 1.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$118.09K | 0.5% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Cardiol Therapeutics Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cardiol Therapeutics Inc Class A working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardiol Therapeutics Inc Class A's current assets represent 99.5% of total assets in 2025, an increase from 77.2% in 2017.
- Cash Position: Cash and equivalents constituted 90.7% of total assets in 2025, up from 73.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 22.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 90.7% of total assets.
Cardiol Therapeutics Inc Class A Competitors by Total Assets
Key competitors of Cardiol Therapeutics Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Cardiol Therapeutics Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.16 | 4.52 | 7.31 |
| Quick Ratio | 4.16 | 4.52 | 7.30 |
| Cash Ratio | 3.79 | 4.36 | 0.00 |
| Working Capital | CA$17.85 Million | CA$24.66 Million | CA$17.45 Million |
Cardiol Therapeutics Inc Class A - Advanced Valuation Insights
This section examines the relationship between Cardiol Therapeutics Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.37 |
| Latest Market Cap to Assets Ratio | 5.54 |
| Asset Growth Rate (YoY) | -25.9% |
| Total Assets | CA$23.62 Million |
| Market Capitalization | $130.88 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cardiol Therapeutics Inc Class A's assets at a significant premium (5.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cardiol Therapeutics Inc Class A's assets decreased by 25.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual total assets of Cardiol Therapeutics Inc Class A from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$23.62 Million ≈ $17.09 Million |
-25.87% |
| 2024-12-31 | CA$31.86 Million ≈ $23.05 Million |
-13.18% |
| 2023-12-31 | CA$36.70 Million ≈ $26.55 Million |
-40.83% |
| 2022-12-31 | CA$62.03 Million ≈ $44.87 Million |
-29.41% |
| 2021-12-31 | CA$87.88 Million ≈ $63.57 Million |
+452.92% |
| 2020-12-31 | CA$15.89 Million ≈ $11.50 Million |
+2.52% |
| 2019-12-31 | CA$15.50 Million ≈ $11.21 Million |
-37.20% |
| 2018-12-31 | CA$24.68 Million ≈ $17.86 Million |
+666.45% |
| 2017-12-31 | CA$3.22 Million ≈ $2.33 Million |
-- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more